Last reviewed · How we verify
Orally antibacterial agents
Orally administered antibacterial agents work by inhibiting bacterial growth and survival through various mechanisms such as cell wall disruption, protein synthesis inhibition, or DNA/RNA interference.
Orally administered antibacterial agents work by inhibiting bacterial growth and survival through various mechanisms such as cell wall disruption, protein synthesis inhibition, or DNA/RNA interference. Used for Bacterial infections (oral formulations for systemic or localized infections).
At a glance
| Generic name | Orally antibacterial agents |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Antibacterial agent (broad category) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This is a broad category encompassing multiple classes of oral antibiotics (e.g., fluoroquinolones, macrolides, beta-lactams, tetracyclines) that each target different bacterial structures or processes. The specific mechanism depends on the individual agent within the class, but all function to either kill bacteria directly or prevent their replication, thereby treating bacterial infections.
Approved indications
- Bacterial infections (oral formulations for systemic or localized infections)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)
- Allergic reactions
- Photosensitivity (with certain classes)
- Headache
Key clinical trials
- PMPR and Chlorhexidine on Periodontal Disease and Vascular Function (NA)
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- SHAPE Pilot Trial: Skin Health and Allergy Prevention Exposure (NA)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Dual-light Antibacterial Photodynamic Therapy as an Adjunctive Treatment to Corticosteroid Treatment in OLP (NA)
- Photodynamic Treatment in the Management of Residual Biofilm - a Crossover Study (NA)
- Regular Home-use of Dual-light Photodynamic Therapy in the Management of Chronic Stage III-IV Periodontitis (NA)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |